Pharming (PHAR) Cash from Investing Activities (2019 - 2025)
Pharming (PHAR) posted Cash from Investing Activities of -$45000.0 for Q4 2025, up 99.54% on a QoQ basis from -$9.8 million in Q4 2024, and up 99.54% year-over-year from -$22551.8 in Q4 2024.
Pharming (PHAR) Cash from Investing Activities (2019 - 2025) Analysis & Trends
Pharming's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$45000.0 for Q4 2025.
- Quarterly Cash from Investing Activities rose 99.54% year-over-year to -$45000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$134.9 million (up 30.14% YoY) and the FY2025 annual result came in at $26.3 million, down 16.97% from the prior year.
- Cash from Investing Activities was -$45000.0 for Q4 2025 at Pharming, up from -$9.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $4.4 million in Q3 2024 and bottomed at -$129.4 million in Q4 2023.
- A 5-year average of -$27.1 million and a median of -$5.0 million in 2021 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities plunged 34403.47% — and 2024, when it soared 107.47%.
- Pharming's Cash from Investing Activities stood at -$2.6 million in 2021, then surged by 85.38% to -$375000.0 in 2022, then plunged by 34403.47% to -$129.4 million in 2023, then surged by 92.43% to -$9.8 million in 2024, then jumped by 99.54% to -$45000.0 in 2025.
- Business Quant data shows PHAR's Cash from Investing Activities at -$45000.0 in Q4 2025, -$9.8 million in Q4 2024, and $4.4 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -45.51 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 178,242.27 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 172.62 Mn |
| 10 | Pharming | 9.02 Bn | 8.96 Bn | 65.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -45,000.00 |
| Dec 31, 2025 | -45,000.00 |
| Dec 31, 2024 | -9.79 Mn |
| Dec 31, 2024 | -9.79 Mn |
| Sep 30, 2024 | 4.35 Mn |
| Sep 30, 2024 | 4.35 Mn |
| Dec 31, 2023 | -129.39 Mn |
| Dec 31, 2023 | -129.39 Mn |
| Sep 30, 2023 | -58.23 Mn |
| Sep 30, 2023 | -58.23 Mn |
| Jun 30, 2023 | -67.25 Mn |
| Jun 30, 2023 | -67.25 Mn |
| Dec 31, 2022 | -375,000.00 |
| Dec 31, 2022 | -375,000.00 |
| Sep 30, 2022 | -298,000.00 |
| Sep 30, 2022 | -298,000.00 |
| Dec 31, 2021 | -2.57 Mn |
| Dec 31, 2021 | -2.57 Mn |
| Sep 30, 2021 | -7.39 Mn |
| Sep 30, 2021 | -7.39 Mn |